On the recommendation of Dr. Steven Smith and with the support of Dean Richard Reznick, Mark Green, Provost and Vice-Principal (Academic) at Queen's University, has appointed Dr. David M. Berman to a second term as Director of the Queen's Cancer Research Institute (QCRI). Dr. Berman has served as Director since January 2015, and his re-appointment commences July 1, 2020.
Dr. Berman earned his BA in Psychology at University of Pennsylvania and combined MD/PhD in Genetics and Development at University of Texas Southwestern Medical School. This was followed by a residency and a postdoctoral fellowship in Pathology/Molecular Biology and Genetics at Johns Hopkins University.
Dr. Berman was appointed as an instructor at Johns Hopkins University in 2001, and was promoted to Associate Professor in 2008. He joined Queen's University in 2012 and is Professor in the Department of Pathology and Molecular Medicine with cross appointments to Oncology and Biomedical and Molecular Sciences. In addition to his role as Director of the QCRI, he served as Director, Division of Cancer Biology and Genetics from 2015 to 2018.
As Director, QCRI, Dr. Berman oversees three divisions: Cancer Biology and Genetics, Cancer Care and Epidemiology, and Canadian Cancer Trials Group (CCTG). The Institute is comprised of 40+ faculty members whose research covers the entire spectrum of cancer research, working as an integrated unit under one roof. Knowledge translation and collaboration is a unique strength of the structure of QCRI, which is proud to celebrate 40 years of clinical trials excellence and innovation by CCTG in 2020.
Dr. Berman's focus on integrated knowledge sharing has attracted distinguished cancer researchers to Queen's from around the world, led to improved collaboration across translational research teams, streamlined institute governance policies, and improved communication through the launch of a comprehensive newsletter that highlights the publications, awards, and innovations of the QCRI's members.
A clinician scientist, Dr. Berman's research and clinical expertise focus on bladder and prostate cancer diagnosis. Since 2015, he has been the PI/Co-PI for research grants totaling more than $5.2 million in funding and has 83 peer-reviewed publications. He continues to work as a classroom and clinical instructor, sharing his expertise in cancer biology and urological pathology.
Please join Dean Reznick in congratulating Dr. Berman on his re-appointment as Director.